Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: Potential for therapy

Endocrine

Volumn 40, Issue 3, 2011, Pages 445-451

  Xu, Yun Ze ^a   Zhu, Yu ^a   Shen, Zhou Jun ^a   Sheng, Jia Yan ^a   He, Hong Chao ^a   Ma, Gui ^a   Qi, Yi Cheng ^a   Zhao, Ju Ping ^a   Wu, Yu Xuan ^a   Rui, Wen Bin ^a   Wei, Qing ^a   Zhou, Wen Long ^a   Xie, Xin ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adrenocortical carcinoma; Heparanase 1; Immunohistochemistry; Microvessel density; Vascular endothelial growth factor; Vascular endothelial growth factor receptor 2

Indexed keywords

HEPARANASE; HEPARANASE 1; HEPARANASE 3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; BETA GLUCURONIDASE; VASCULOTROPIN A;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSEL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION; ADENOMA; ADRENAL CORTEX TUMOR; CARCINOMA; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SINGLE BLIND PROCEDURE; VASCULARIZATION;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; CARCINOMA; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SINGLE-BLIND METHOD; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84858758545     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9502-1     Document Type: Article

References (36)

1. M. Fassnacht, R. Libe, M. Kroiss et al., Adrenocortical carcinoma: a clinician's update. Nat. Rev. Endocrinol. 7, 323-335 (2011)
2. B. Allolio, M. Fassnacht, Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 91, 2027-2037 (2006) (Pubitemid 43854976)
3. M. Fassnacht, B. Allolio, What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin. Endocrinol. (Oxf) 73, 561-565 (2010)
4. A. Berruti, M. Fassnacht, E. Baudin et al., Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J. Clin. Oncol. 28, 401-403 (2010)
5. D.E. Schteingart, G.M. Doherty, P.G. Gauger et al., Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer 12, 667-680 (2005) (Pubitemid 41483000)
6. I.J. Fidler, L.M. Ellis, The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188 (1994) (Pubitemid 24324908)
7. N. Ferrara, Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell. Physiol. 280, C1358-C1366 (2001) (Pubitemid 32553190)
8. N. Weidner, Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9-19 (1995)
9. H. Sawai, Y. Okada, H. Funahashi et al., Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells. J. Surg. Res. 144, 117-123 (2008) (Pubitemid 350234953)
10. M. Bernfield, M. Gotte, P.W. Park et al., Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777 (1999) (Pubitemid 29449208)
11. C.R. Parish, C. Freeman, M.D. Hulett, Heparanase: a key enzyme involved in cell invasion. Biochim. Biophys. Acta 1471, M99-M108 (2001) (Pubitemid 32206686)
12. I. Vlodavsky, Y. Friedmann, Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347 (2001) (Pubitemid 32730777)
13. H. Wang, J.L. Si, X.Z. Zhang et al., Expression and clinical significance of syndecan-1 mRNA and HPA-1 mRNA in colorectal cancer detected with real-time fluorescent quantitative polymerase chain reaction. Chin. J. Cancer 29, 288-293 (2010)
14. K.S. Rohrberg, B.G. Skov, U. Lassen et al., Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer. Cancer Biomark. 7, 141-151 (2010)
15. U. Yildirim, H. Erdem, A. Kayikci et al., Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density. J. Int. Med. Res. 38, 1689-1699 (2010)
16. J.C. Yang, L. Haworth, R.M. Sherry et al., A randomized trial of bevacizumab an anti-vascular endothelial growth factor antibody for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003) (Pubitemid 36910021)
17. A. Sandler, R. Gray, M.C. Perry et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006) (Pubitemid 44917502)
18. B. Ramaswamy, A.D. Elias, N.T. Kelbick et al., Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin. Cancer Res. 12, 3124-3129 (2006) (Pubitemid 43837360)
19. S. Wortmann, M. Quinkler, C. Ritter et al., Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol. 162, 349-356 (2010)
20. L.M. Weiss, L.J. Medeiros Jr, A.L. Vickery, Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 13, 202-206 (1989) (Pubitemid 19081702)
21. R. Kouyama, K. Hiraishi, T. Sugiyama et al., Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma. Endocr. J. 2011 Apr 27. [Epub ahead of print]
22. Y. Kitadai, K. Haruma, T. Tokutomi et al., Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin. Cancer Res. 4, 2195-2200 (1998) (Pubitemid 28415667)
23. Y. Zhu, H.C. He, F. Yuan et al., Heparanase-1 and cyclooxygenase- 2: prognostic indicators of malignancy in pheochromocytomas. Endocrine 38, 93-99 (2010)
24. I. Veytsman, L. Nieman, T. Fojo, Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J. Clin. Oncol. 27, 4619-4629 (2009)
25. I.G. Hermsen, M. Fassnacht, M. Terzolo et al., Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a Retrospective ENS@T Multicenter Study. J. Clin. Endocrinol. Metab. 96, 1844-1851 (2011)
26. M. Fassnacht, S. Johanssen, M. Quinkler et al., Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115, 243-250 (2009)
27. T.J. Giordano, R. Kuick, T. Else et al., Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668-676 (2009)
28. A. de Reynies, G. Assie, D.S. Rickman et al., Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 27, 1108-1115 (2009)
29. J.B. Laforga, F.I. Aranda, Angiogenic index: a new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6, 103-107 (2000) (Pubitemid 30227088)
30. S.J. Diaz-Cano, M. de Miguel, A. Blanes, H. Galera, H.J. Wolfe, Contribution of the microvessel network to the clonal and kinetic profiles of adrenal cortical proliferative lesions. Hum. Pathol. 32, 1232-1239 (2001) (Pubitemid 33104435)
31. R.S. Kerbel, Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008) (Pubitemid 351656458)
32. S. Zacharieva, I. Atanassova, M. Orbetzova et al., Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur. J. Endocrinol. 150, 345-349 (2004) (Pubitemid 38443785)
33. F. de Fraipont, M. El Atifi, C. Gicquel et al., Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 85, 4734-4741 (2000) (Pubitemid 32157660)
34. M.D. Hulett, C. Freeman, B.J. Hamdorf et al., Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat. Med. 5, 803-809 (1999) (Pubitemid 29318615)
35. K. Gohji, H. Hirano, M. Okamoto et al., Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95, 295-301 (2001) (Pubitemid 32847039)
36. M. Elkin, N. Ilan, R. Ishai-Michaeli et al., Heparanase as mediator of angiogenesis: mode of action. FASEB. J. 15, 1661-1663 (2001)